Off air

Continuing story · 1 report

Trump administration's ibogaine fast-track effort

First aired Latest aired

DevelopingNext check : Whether the administration or FDA abandons the effort, or the FDA completes a decision on ibogaine’s development or approval pathway.

Where it stands

As of July 23, 2026, the Trump administration was pushing to fast-track ibogaine for addiction treatment, while experts cited cardiac risks linked to potentially fatal arrhythmias. The report identifies Trump and the FDA as decision-makers but gives no decision, next step or indication that the effort has been abandoned.

Story trackerDay 1

1 report11 outlets11 sources1 video

The story so far

  1. Update 1

    Twenty-Seven Dead, No FDA Approval, and a Presidential Pen

    Trump's April executive order fast-tracks ibogaine, a Schedule I psychedelic with documented cardiac risk, while Americans keep dying at unregulated clinics abroad.

    Still open after this report

    • The full death toll at foreign clinics, including non-American patients, is not publicly tracked.
    • How the FDA will interpret "expedite" — whether it fast-tracks a specific application or reopens the research pathway — has not been disclosed.
    • Whether Texas's state-funded trials will produce randomized data sufficient for an FDA submission.

History

  1. Opened1 report

Who's involved

People

  • Céline GounderAmerican infectious disease physician, internist, epidemiologist, filmmaker, and medical journalist1 report
  • Donald TrumpPresident of the United States (2017–2021; since 2025)1 report
  • Joe RoganAmerican broadcaster, comedian, and actor (born 1967)1 report

Places

  • MexicoMexico1 report
  • Stanford University450 Jane Stanford Way, Stanford, CA 94305, USA1 report
  • TexasTexas, USA1 report
  • The Oval Office1600 Pennsylvania Ave NW, Washington, DC 20500, USA1 report

Every outlet we read on this story

11 sources11 outlets1 video